BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38479545)

  • 21. Astragalus polysaccharide attenuates LPS-related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway.
    Yang J; Qin L; Huang J; Li Y; Xu S; Wang H; Zhu S; Wang J; Zhu B; Li F; Huang W; Gong X; Hu N
    J Cell Mol Med; 2021 Jul; 25(14):6800-6814. PubMed ID: 34080298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations.
    Tang J; Feng Y; Tsao S; Wang N; Curtain R; Wang Y
    J Ethnopharmacol; 2009 Oct; 126(1):5-17. PubMed ID: 19686830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
    Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
    Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
    Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways.
    Wu Z; Wu H; Li C; Fu F; Ding J; Shao S; Li K; Yu X; Su Y; Liang J; Lin X; Yuan G; Zhou J; Song F; Zhao J; Xu J; Liu Q; Xu F
    J Cell Physiol; 2019 Aug; 234(10):17812-17823. PubMed ID: 30815894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
    Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
    Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
    [No Abstract]   [Full Text] [Related]  

  • 27. Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model.
    Xiao F; Zhai Z; Jiang C; Liu X; Li H; Qu X; Ouyang Z; Fan Q; Tang T; Qin A; Gu D
    Exp Cell Res; 2015 Jan; 330(1):91-101. PubMed ID: 25016282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Astragalin mitigates inflammatory osteolysis by negatively modulating osteoclastogenesis via ROS and MAPK signaling pathway.
    Xing F; Geng L; Guan H; Liu D; Li Y; Zeng L; Chen Y; Tian R; Li Z; Cao R; Zhao Y; Yan P; Qiang H; Kong N; Wang K; Yang P
    Int Immunopharmacol; 2022 Nov; 112():109278. PubMed ID: 36215870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epothilone B prevents lipopolysaccharide-induced inflammatory osteolysis through suppressing osteoclastogenesis via STAT3 signaling pathway.
    Chen Y; Wang Y; Hu J; Tang Y; Tian Z; Hu W; Zeng F; Tan J; Dai Q; Hou Z; Luo F; Xu J; Dong S
    Aging (Albany NY); 2020 Jun; 12(12):11698-11716. PubMed ID: 32527985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.
    Zhang Y; Zou B; Tan Y; Su J; Wang Y; Xu J; Tao L; Zhou H; Liu L; Li X
    Pharmacol Res; 2019 Apr; 142():140-150. PubMed ID: 30797069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives.
    Wang N; Tan HY; Li L; Yuen MF; Feng Y
    J Ethnopharmacol; 2015 Dec; 176():35-48. PubMed ID: 26494507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
    Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
    Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse model.
    Huang J; Zhou L; Wu H; Pavlos N; Chim SM; Liu Q; Zhao J; Xue W; Tan RX; Ye J; Xu J; Ang ES; Feng H; Tickner J; Xu J; Ding Y
    Mol Cell Endocrinol; 2015 Jan; 399():346-53. PubMed ID: 25448849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arctigenin inhibits RANKL-induced osteoclastogenesis and hydroxyapatite resorption in vitro and prevents titanium particle-induced bone loss in vivo.
    Wei G; Liang T; Wei C; Nong X; Lu Q; Zhao J
    J Cell Biochem; 2019 Apr; 120(4):5367-5376. PubMed ID: 30317692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
    Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
    Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
    Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
    Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
    Marino S; Bishop RT; Mollat P; Idris AI
    Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.